03 Jul 2017
N+1 Singer - Oxford BioMedica - Debt facility refinanced
Oxford BioMedica has secured a new $55m debt facility with Oaktree, enabling it to redeem its existing $50m facility with Oberland. The new facility has more favourable terms. We continue to look forward to regulatory approval of Novartis’ CTL019 for acute lymphoblastic leukaemia, on which Oxford BioMedica is eligible to a royalty on sales. The group remains confident of supplying the vector following launch (our forecasts assume 2017) having supplied the lentiviral vector for its clinical trial ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Debt facility refinanced
Oxford BioMedica plc (OXB:LON) | 218 7.6 1.6% | Mkt Cap: 218.3m
- Published:
03 Jul 2017 -
Author:
Sheena Berry -
Pages:
4
Oxford BioMedica has secured a new $55m debt facility with Oaktree, enabling it to redeem its existing $50m facility with Oberland. The new facility has more favourable terms. We continue to look forward to regulatory approval of Novartis’ CTL019 for acute lymphoblastic leukaemia, on which Oxford BioMedica is eligible to a royalty on sales. The group remains confident of supplying the vector following launch (our forecasts assume 2017) having supplied the lentiviral vector for its clinical trial ....